Although Pacritinib remains on full clinical hold, the FDA recently indicated to CTI BioPharma they would allow patients who were receiving benefit from Pacritinib treatment at the time the clinical hold was imposed to resume Pacritinib treatment under a Single Patient IND (SPI)/Compassionate Use program. In response, CTI BioPharma has developed a program that will allow patients access to Pacritinib and will be providing clinical investigators worldwide with specific details regarding implementation of this program. Patients should contact their doctor for more information. We’ll post updates as they become available.
PACRITINIB REMAINS ON FULL CLINICAL HOLD BUT FDA OKS INDIVIDUAL INDS
MPNRF | April 29, 2021